Portola Pharmaceuticals Inc. chalked up a development and commercial deal for andexanet alfa in Japan with Bristol-Myers Squibb Co. (BMS) and Pfizer Inc., under which the compound will be explored further as an antidote for the latter pair’s therapy Eliquis (apixaban) and the “mega-blockbuster class” that includes other Factor Xa inhibitors as well.